The Surging Prevalence Of Age-Related Macular Degeneration Sparks Growth In The AMD Market: Transformative Forces Shaping the Age-Related Macular Degeneration Market Landscape in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Age-Related Macular Degeneration Industry Market Size Be by 2025?
The market specifically addressing age-related macular degeneration has experienced a robust expansion of late, projected to increase its valuation from $9.96 billion in 2024 to $10.67 billion the following year, reflecting a consistent compound annual growth rate of 7.1%; this historical upward trend is primarily influenced by demographic shifts toward older populations, evolving personal habits and external surroundings, inherited vulnerabilities, greater public consciousness leading to earlier detection, and progress in the methodologies used for diagnosis.

What's the Long-Term Growth Forecast for the Age-Related Macular Degeneration Market Size Through 2029?
Anticipating substantial expansion, the market dedicated to age-related macular degeneration is projected to reach a valuation of $14.29 billion by the year 2029, exhibiting a compound annual growth rate (CAGR) of 7.6% throughout the projection timeframe; this upward momentum is fueled by ongoing investigations into genetic factors and biomarkers, the introduction of novel treatment methods, the increasing utilization of telemedicine and remote patient oversight, alongside heightened patient awareness and educational initiatives. Key developments shaping this market during the forecast incorporate the shift toward individualized medical treatments, advancements in technology for retinal visualization, the advent of drug delivery mechanisms designed for prolonged effectiveness, ongoing clinical assessments of promising experimental treatments, and strategic partnerships established to further research and development efforts.

View the full report here:
https://www.thebusinessresearchcompany.com/report/age-related-macular-degeneration-global-market-report

What Are the Key Growth Drivers Fueling the Age-Related Macular Degeneration Market Expansion?
The increasing rate of age-related macular degeneration (AMD) incidence is forecast to be the main catalyst for expanding the age-related macular degeneration (AMD) market moving ahead. AMD constitutes a degenerative ocular ailment impacting the macula, which is the specific retinal section critical for central sight. Therapies available for age-related macular degeneration (AMD) assist individuals dealing with retinal pathologies by mitigating the seriousness of the ailment. To illustrate this accelerating issue, data released in February 2023 by Optimaxa, a specialist in laser vision correction based in the UK, indicated that 196 million people worldwide were afflicted by age-related macular degeneration (AMD), a figure projected to climb to 288 million by the year 2040, representing 8.7 percent of the global populace; consequently, this escalating prevalence of age-related macular degeneration (AMD) is fueling the growth trajectory of the age-related macular degeneration market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp

What Are the Key Trends Driving Age-Related Macular Degeneration Market Growth?
Within the competitive landscape of age-related macular degeneration (AMD) treatments, leading corporations are actively pioneering novel therapeutic modalities, notably including bispecific antibodies engineered to decrease the necessary frequency of patient administration. Such a bispecific antibody represents a specially designed immunological agent possessing the capability to attach itself simultaneously to two distinct antigenic targets. As an illustration, the Japanese pharmaceutical entity Chugai Pharmaceutical Co., Ltd. introduced Vabysmo, an intravitreal injection dosed at 120 mg/mL, in May 2022, which functions as a bispecific antibody specifically formulated for managing ocular pathologies such as AMD and diabetic macular edema (DME). This pioneering medical intervention exerts its therapeutic effect by simultaneously interacting with two critical biological pathways: angiopoietin-2 (Ang-2), a protein implicated in the proliferation of aberrant blood vessels and inflammatory processes, and Vascular Endothelial Growth Factor-A (VEGF-A), which is central to the development of neovascularization causing visual impairment. A significant advantage conferred by Vabysmo is its capacity to support extended dosing schedules, allowing for treatment intervals of up to 16 weeks, thereby improving patient compliance and overall ease of management. This mechanism, involving the targeting of two factors concurrently, signifies a major advancement in care for eye conditions, meeting the critical demand for dependable therapeutic solutions for retinal disorders.

How Is the Age-Related Macular Degeneration Market Segmented?
The age-related macular degenerationmarket covered in this report is segmented -

1) By Type: Wet Age-Related Macular Degeneration (AMD); Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea; Lucentis; Avastin; Other Products
3) By Route Of Administration: Intravenous; Intravitreal
4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy; Online Pharmacy

Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections; Photodynamic Therapy; Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements; Low Vision Aids; Therapies For Geographic Atrophy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10845&type=smp

Which Companies Are Leading the Charge in Age-Related Macular Degeneration Market Innovation?
Major companies operating in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

Which Regions Are Leading the Global Age-Related Macular Degeneration Market in Revenue?
North America was the largest region in the global age-related macular degeneration market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10845

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.